HA‐based nanoparticles are considered to be an effective system to easily deliver anticancer drugs into the CD44‐overexpressing tumour cells through the receptor‐mediated endocytosis, and the subsequent enzymatic degradation results in the sustained release of the nanoparticle's content 103, 104. The gene discussed is CD44; the disease is neoplasm.